Truist Securities Maintains Buy on BeOne Medicines, Raises Price Target to $418

Benzinga · 1d ago
Truist Securities analyst Gregory Renza maintains BeOne Medicines (NASDAQ:ONC) with a Buy and raises the price target from $416 to $418.